Metropolis Healthcare Limited has successfully completed its postal ballot process for bonus shares issuance and has now announced the implementation timeline. Following overwhelming shareholder approval with 98.36% votes in favor, the company has fixed March 20, 2026 as the record date for determining shareholder entitlement for the 3:1 bonus equity shares issuance.

Record Date and Implementation Timeline

The Board of Directors, through a Circular Resolution passed on March 10, 2026, has established the complete implementation framework for the bonus shares issuance. The company communicated these details to stock exchanges through reference MHL/Sec&Legal/2025-26/97.

Shareholder Approval and Voting Results

The postal ballot process concluded with decisive shareholder support, demonstrating strong confidence in the company's capital restructuring initiative. Sunny Gogiya from SGGS & Associates served as the scrutinizer for the comprehensive vote counting process.

E-Voting Process and Documentation

The postal ballot was conducted exclusively through electronic voting, with National Securities Depository Limited serving as the Electronic Voting Service Provider. The e-voting period commenced on February 07, 2026 at 09:00 a.m. IST and concluded on March 08, 2026 at 05:00 p.m. IST.

Kamlesh C Kulkarni, Head – Legal & Secretarial, submitted the scrutinizer's report on March 09, 2026, confirming compliance with all regulatory requirements under Sections 108 and 110 of the Companies Act, 2013, and Regulation 44 of SEBI Listing Regulations.

Regulatory Compliance Framework

The bonus shares implementation follows SEBI Circular No. CIR/CFD/PoD/2024/122 dated September 16, 2024, which establishes the deemed allotment date framework. The entire process maintains transparency with voting results available on multiple platforms including the company's website at www.metropolisindia.com , NSDL's portal, and stock exchange websites.

Metropolis Healthcare Limited announced its Q3FY26 quarterly results for the quarter ended December 31, 2025, demonstrating robust financial performance alongside significant corporate developments. The diagnostic services company's Board of Directors approved comprehensive quarterly results and strategic initiatives during their meeting held on February 4, 2026.

Strong Financial Performance

The company delivered impressive consolidated financial results with revenue reaching ₹4.06 billion compared to ₹3.2 billion in the corresponding quarter of the previous year, marking substantial growth year-on-year. Consolidated net profit demonstrated strong momentum at ₹414 million versus ₹314 million in the year-ago quarter, representing a robust 31% increase.

Operational Excellence and Margin Expansion

The company's operational performance showcased significant improvement with EBITDA reaching ₹948 million compared to ₹720 million in the year-ago quarter, reflecting a strong 32% year-on-year growth. EBITDA margin expanded to 23.36% from 22.31% in the corresponding quarter of the previous year, demonstrating enhanced operational efficiency and productivity gains across the diagnostic services portfolio.

Major Corporate Developments

The Board of Directors approved several significant strategic initiatives during their meeting. Most notably, they recommended a bonus issue of equity shares in the proportion of 3:1, meaning shareholders will receive 3 fully paid-up equity shares of face value INR 2 each for every 1 existing share held. The bonus issue is subject to members, statutory and regulatory approvals, with the record date to be announced in due course.

Regulatory Filing and Investor Presentation

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company filed its investor presentation for the quarter ended December 31, 2025, on February 04, 2026. The presentation, signed by Kamlesh C Kulkarni, Head Legal & Secretarial, has been uploaded on the company's website at www.metropolisindia.com and provides comprehensive insights into the company's Q3FY26 performance.

The meeting commenced at 11:15 AM IST and concluded at 3:40 PM IST, with comprehensive discussions on quarterly performance and strategic initiatives that position the company for continued growth in the diagnostic services sector.